Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
EW Analyst Ratings
Moderate Buy
14 Buy
10 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
EW Stock 12 Month Forecast
Average Price Target
$95.10
▲(10.34% Upside)
| Highest Price Target$104.00 | Average Price Target$95.10 | Lowest Price Target$84.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Truist Financial
$90→$92
Hold
6.74%
Upside
Reiterated
12/05/25
Jefferies
$102
Buy
18.34%
Upside
Reiterated
12/05/25
Robert W. Baird
$83→$88
Hold
2.10%
Upside
Reiterated
12/05/25
Wells Fargo
$95→$96
Buy
11.38%
Upside
Reiterated
12/05/25
UBS
$90→$92
Hold
6.74%
Upside
Reiterated
12/05/25
Canaccord Genuity
$84→$89
Hold
3.26%
Upside
Reiterated
12/05/25
Stifel Nicolaus
$95→$100
Buy
16.02%
Upside
Reiterated
12/05/25
BTIG
$100→$103
Buy
19.50%
Upside
Reiterated
12/05/25
Edwards Lifesciences: Strategic Initiatives and Promising Developments Drive Raised Price TargetWe expect 2026 to be a catalyst- rich year for EW in TAVR as well as its transcatheter mitral and tricuspid therapies (TMTT) segments. Positive TAVR tailwinds could come from the recent shift in valvular guidelines (ASE and ESC/EACTS updates) that streamlines referrals and treatment for all severe AS patients independent of symptoms, more guideline updates to come (AHA/ACC anticipated in 4Q26), and a potential national coverage determination (NCD) update now estimated for 4Q26. We think this means CMS could open the NCD very soon. In TMTT, EW reiterated its goal of reaching $2B in sales by 2030 (~30% CAGR), supported by its broad portfolio of repair and replacement devices. Sapien M3 is expected to receive FDA approval early next year, more data will be shared on Evoque, and later in the year we'll see FDA approval of Pascal for TR and a next-gen device.
RBC Capital
$95→$100
Buy
16.02%
Upside
Reiterated
12/04/25
TD Cowen
$84→$90
Hold
4.42%
Upside
Reiterated
12/04/25
William Blair
―
Buy
―
Reiterated
12/04/25
Edwards Lifesciences: A Strong Growth Opportunity in Medtech with Expanding Market Potential and Robust Product PortfolioWe attended Edwards’s annual investor day, which ultimately reiterated our bullish thesis for durable double-digit top- and bottom-line growth. At a high level, the investor day reiterated two key points of our thesis: 1) Edwards has a robust pipeline of clinical data and new products that are expanding its TAM into markets as large, or in some cases larger, than the current TAVR the breadth of the company’s portfolio (i.e., repair and replacement offerings for multiple valves) and clinical backing (i.e., breadth and length of follow-up clinical data) is putting them in one of the most competitive positions it has been in over a decade. These two points should compound as the company expands its addressable market and potentially even takes share in existing core markets.
Bank of America Securities
$103
Buy
19.50%
Upside
Reiterated
12/03/25
Piper Sandler
$95
Buy
10.22%
Upside
Reiterated
12/02/25
Barclays
$99
Buy
14.86%
Upside
Reiterated
12/02/25
Raymond James
$96
Buy
11.38%
Upside
Upgraded
11/03/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Truist Financial
$90→$92
Hold
6.74%
Upside
Reiterated
12/05/25
Jefferies
$102
Buy
18.34%
Upside
Reiterated
12/05/25
Robert W. Baird
$83→$88
Hold
2.10%
Upside
Reiterated
12/05/25
Wells Fargo
$95→$96
Buy
11.38%
Upside
Reiterated
12/05/25
UBS
$90→$92
Hold
6.74%
Upside
Reiterated
12/05/25
Canaccord Genuity
$84→$89
Hold
3.26%
Upside
Reiterated
12/05/25
Stifel Nicolaus
$95→$100
Buy
16.02%
Upside
Reiterated
12/05/25
BTIG
$100→$103
Buy
19.50%
Upside
Reiterated
12/05/25
Edwards Lifesciences: Strategic Initiatives and Promising Developments Drive Raised Price TargetWe expect 2026 to be a catalyst- rich year for EW in TAVR as well as its transcatheter mitral and tricuspid therapies (TMTT) segments. Positive TAVR tailwinds could come from the recent shift in valvular guidelines (ASE and ESC/EACTS updates) that streamlines referrals and treatment for all severe AS patients independent of symptoms, more guideline updates to come (AHA/ACC anticipated in 4Q26), and a potential national coverage determination (NCD) update now estimated for 4Q26. We think this means CMS could open the NCD very soon. In TMTT, EW reiterated its goal of reaching $2B in sales by 2030 (~30% CAGR), supported by its broad portfolio of repair and replacement devices. Sapien M3 is expected to receive FDA approval early next year, more data will be shared on Evoque, and later in the year we'll see FDA approval of Pascal for TR and a next-gen device.
RBC Capital
$95→$100
Buy
16.02%
Upside
Reiterated
12/04/25
TD Cowen
$84→$90
Hold
4.42%
Upside
Reiterated
12/04/25
William Blair
―
Buy
―
Reiterated
12/04/25
Edwards Lifesciences: A Strong Growth Opportunity in Medtech with Expanding Market Potential and Robust Product PortfolioWe attended Edwards’s annual investor day, which ultimately reiterated our bullish thesis for durable double-digit top- and bottom-line growth. At a high level, the investor day reiterated two key points of our thesis: 1) Edwards has a robust pipeline of clinical data and new products that are expanding its TAM into markets as large, or in some cases larger, than the current TAVR the breadth of the company’s portfolio (i.e., repair and replacement offerings for multiple valves) and clinical backing (i.e., breadth and length of follow-up clinical data) is putting them in one of the most competitive positions it has been in over a decade. These two points should compound as the company expands its addressable market and potentially even takes share in existing core markets.
Bank of America Securities
$103
Buy
19.50%
Upside
Reiterated
12/03/25
Piper Sandler
$95
Buy
10.22%
Upside
Reiterated
12/02/25
Barclays
$99
Buy
14.86%
Upside
Reiterated
12/02/25
Raymond James
$96
Buy
11.38%
Upside
Upgraded
11/03/25
Best Analysts Covering Edwards Lifesciences
1 Month
xxx
Success Rate
28/40 ratings generated profit
Average Return
+2.10%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of +2.10% per trade.
3 Months
xxx
Success Rate
17/23 ratings generated profit
Average Return
+3.35%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 73.91% of your transactions generating a profit, with an average return of +3.35% per trade.
1 Year
2 Years
xxx
Success Rate
16/23 ratings generated profit
Average Return
+11.30%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 69.57% of your transactions generating a profit, with an average return of +11.30% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
EW Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
0
0
0
0
0
Buy
34
36
39
32
36
Hold
23
22
19
16
20
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
57
58
58
48
56
Each month's total comprises the sum of three months' worth of ratings.
EW Financial Forecast
EW Stock Forecast FAQ
What is EW’s average 12-month price target, according to analysts?
Based on analyst ratings, Edwards Lifesciences’s 12-month average price target is 95.10.
What is EW’s upside potential, based on the analysts’ average price target?
Edwards Lifesciences has 10.34% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is EW a Buy, Sell or Hold?
Edwards Lifesciences has a consensus rating of Moderate Buy which is based on 14 buy ratings, 10 hold ratings and 0 sell ratings.
What is Edwards Lifesciences’s price target?
The average price target for Edwards Lifesciences is 95.10. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $104.00 ,the lowest forecast is $84.00. The average price target represents 10.34% Increase from the current price of $86.19.
The highest analyst price target is $104.00 ,the lowest forecast is $84.00. The average price target represents 10.34% Increase from the current price of $86.19.
What do analysts say about Edwards Lifesciences?
Edwards Lifesciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 24 Wall Streets Analysts.
How can I buy shares of EW?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.